MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study
Geoffrey Liu(Princess Margaret Cancer Centre), Lyudmila Bazhenova(Memorial Sloan Kettering Cancer Center), Noriko Yanagitani(The Cancer Institute Hospital), Rose Lai, C. Zhou(Tongji University), C.-M. Choi(Ulsan College), J. Nieva(USC Norris Comprehensive Cancer Center), M. Pérol(Centre Léon Bérard), Nengcong Yang(Central South University), Misako Nagasaka(University of California, Irvine), X. Zhang(Nuvotronics (United States)), Shunichi Sugawara(Sendai Kousei Hospital), E. Felip, Yuichiro Ohe(National Cancer Center), Nathan A. Pennell(Cleveland Clinic), Shouqiang Li(Io Therapeutics (United States)), Filippo de Braud(University of Milan)
Cited by 4
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k